Effect of ribociclib Plus fulvestrant on overall survival in the treatment of advanced breast cancer - updated MONALEESA-3 results

被引：0
作者：
Dubianski, Roman [1 ]
机构：
[1] Maria Sklodowska Curie Natl Res Inst Oncol, Dept Breast Canc & Reconstruct Surg, WK Roentgena 5 St, PL-02781 Warsaw, Poland
来源：
ONCOLOGY IN CLINICAL PRACTICE | 2022年 / 18卷 / 03期
关键词：
breast cancer; ribociclib; fulvestrant; CDK4/6; inhibitor; PHASE-I; TRIAL; THERAPY;
D O I：
10.5603/OCP.2021.0034
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
The results of the treatment of ER-positive/HER2-negative advanced breast cancer have been improved in the last few years due to the use of CDK4/6 inhibitors combined with endocrine therapy. Ribociclib with fulvestrant significantly prolonged progression-free survival and overall survival in the phase-III MONALEESA-3 trial. The newest update of the trial (after 56.3 months of observation) showed significant improvement in overall survival in the experimental arm for more than ayear: mOS was 53.7 months in the ribociclib plus fulvestrant arm and 41.5 months in the placebo plus fulvestrant arm (risk reduction of 27%). Subgroup analysis confirmed the efficacy of the treatment in both the first and second lines of treatment. The study also showed that adding ribociclib to the endocrine treatment prolongs the median time to chemotherapy. No new toxicities were observed in longer observation.
引用
收藏
页码：189 / 194
页数：6
相关论文
共 21 条
  • [1] Integrative Analysis of Cyclin Protein Levels Identifies Cyclin B1 as a Classifier and Predictor of Outcomes in Breast Cancer
    Agarwal, Roshan
    Gonzalez-Angulo, Ana-Maria
    Myhre, Simen
    Carey, Mark
    Lee, Ju-Seog
    Overgaard, Jens
    Alsner, Jan
    Stemke-Hale, Katherine
    Lluch, Ana
    Neve, Richard M.
    Kuo, Wen Lin
    Sorlie, Therese
    Sahin, Aysegul
    Valero, Vicente
    Keyomarsi, Khandan
    Gray, Joe W.
    Borresen-Dale, Anne-Lise
    Mills, Gordon B.
    Hennessy, Bryan T.
    [J]. CLINICAL CANCER RESEARCH, 2009, 15 (11) : 3654 - 3662
  • [2] Cyclin D1 in breast cancer pathogenesis
    Arnold, A
    Papanikolaou, A
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (18) : 4215 - 4224
  • [3] 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5)
    Cardoso, F.
    Paluch-Shimon, S.
    Senkus, E.
    Curigliano, G.
    Aapro, M. S.
    Andre, F.
    Barrios, C. H.
    Bergh, J.
    Bhattacharyya, G. S.
    Biganzoli, L.
    Boyle, F.
    Cardoso, M-J
    Carey, L. A.
    Cortes, J.
    El Saghir, N. S.
    Elzayat, M.
    Eniu, A.
    Fallowfield, L.
    Francis, P. A.
    Gelmon, K.
    Gligorov, J.
    Haidinger, R.
    Harbeck, N.
    Hu, X.
    Kaufman, B.
    Kaur, R.
    Kiely, B. E.
    Kim, S-B
    Lin, N. U.
    Mertz, S. A.
    Neciosup, S.
    Offersen, B., V
    Ohno, S.
    Pagani, O.
    Prat, A.
    Penault-Llorca, F.
    Rugo, H. S.
    Sledge, G. W.
    Thomssen, C.
    Vorobiof, D. A.
    Wiseman, T.
    Xu, B.
    Norton, L.
    Costa, A.
    Winer, E. P.
    [J]. ANNALS OF ONCOLOGY, 2020, 31 (12) : 1623 - 1649
  • [4] A cell-type-specific transcriptional network required for estrogen regulation of cyclin D1 and cell cycle progression in breast cancer
    Eeckhoute, Jerome
    Carroll, Jason S.
    Geistlinger, Timothy R.
    Torres-Arzayus, Maria I.
    Brown, Myles
    [J]. GENES & DEVELOPMENT, 2006, 20 (18) : 2513 - 2526
  • [5] ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer
    Gennari, A.
    Andre, F.
    Barrios, C. H.
    Cortes, J.
    de Azambuja, E.
    DeMichele, A.
    Dent, R.
    Fenlon, D.
    Gligorov, J.
    Hurvitz, S. A.
    Im, S. -a.
    Krug, D.
    Kunz, W. G.
    Loi, S.
    Penault-Llorca, F.
    Ricke, J.
    Robson, M.
    Rugo, H. S.
    Saura, C.
    Schmid, P.
    Singer, C. F.
    Spanic, T.
    Tolaney, S. M.
    Turner, N. C.
    Curigliano, G.
    Loibl, S.
    Paluch-Shimon, S.
    Harbeck, N.
    [J]. ANNALS OF ONCOLOGY, 2021, 32 (12) : 1475 - 1495
  • [6] Overall survival (OS) results from the phase III MONALEESA-2 (ML-2) trial of postmenopausal patients (pts) with hormone receptor positive/human epidermal growth factor receptor 2 negative (HR+/HER2L) advanced breast cancer (ABC) treated with endocrine therapy (ET) ± ribociclib (RIB)
    Hortobagyi, G. N.
    Stemmer, S. M.
    Burris, H. A., III
    Yap, Y. S.
    Sonke, G. S.
    Hart, L.
    Campone, M.
    Petrakova, K.
    Winer, E. P.
    Janni, W.
    Conte, P. F.
    Cameron, D.
    Andre, F.
    Arteaga, C.
    Zarate, J. P.
    Chakravartty, A.
    Taran, T.
    Le Gac, F.
    Serra, P.
    O'Shaughnessy, J.
    [J]. ANNALS OF ONCOLOGY, 2021, 32 : S1290 - S1291
  • [7] Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer
    Hortobagyi, G. N.
    Stemmer, S. M.
    Burris, H. A.
    Yap, Y. S.
    Sonke, C. S.
    Paluch-Shimon, S.
    Campone, M.
    Petrakova, K.
    Blackwell, K. L.
    Winer, E. P.
    Janni, W.
    Verma, S.
    Conte, P.
    Arteaga, C. L.
    Cameron, D. A.
    Mondal, S.
    Su, F.
    Miller, M.
    Elmeliegy, M.
    Germa, C.
    O'Shaughnessy, J.
    [J]. ANNALS OF ONCOLOGY, 2018, 29 (07) : 1541 - 1547
  • [8] Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer
    Hortobagyi, G. N.
    Stemmer, S. M.
    Burris, H. A.
    Yap, Y. -S.
    Sonke, G. S.
    Paluch-Shimon, S.
    Campone, M.
    Blackwell, K. L.
    Andre, F.
    Winer, E. P.
    Janni, W.
    Verma, S.
    Conte, P.
    Arteaga, C. L.
    Cameron, D. A.
    Petrakova, K.
    Hart, L. L.
    Villanueva, C.
    Chan, A.
    Jakobsen, E.
    Nusch, A.
    Burdaeva, O.
    Grischke, E. -M.
    Alba, E.
    Wist, E.
    Marschner, N.
    Favret, A. M.
    Yardley, D.
    Bachelot, T.
    Tseng, L. -M.
    Blau, S.
    Xuan, F.
    Souami, F.
    Miller, M.
    Germa, C.
    Hirawat, S.
    O'Shaughnessy, J.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2016, 375 (18) : 1738 - 1748
  • [9] A Phase I Study of the Cyclin-Dependent Kinase 4/6 Inhibitor Ribociclib (LEE011) in Patients with Advanced Solid Tumors and Lymphomas
    Infante, Jeffrey R.
    Cassier, Philippe A.
    Gerecitano, John F.
    Witteveen, Petronella O.
    Chugh, Rashmi
    Ribrag, Vincent
    Chakraborty, Abhijit
    Matano, Alessandro
    Dobson, Jason R.
    Crystal, Adam S.
    Parasuraman, Sudha
    Shapiro, Geoffrey I.
    [J]. CLINICAL CANCER RESEARCH, 2016, 22 (23) : 5696 - 5705
  • [10] Jassem J, 2020, Oncol Clin Pract, P16, DOI [10.5603/OCP.2020.0038, DOI 10.5603/OCP.2020.0038]
123